Clinical Trial Update: Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the efficacy and safety of DA-1241 in nonalcoholic steatohepatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• DA-1241

Snippet

Sponsor: NeuroBo Pharmaceuticals Inc. | Conditions: NON-ALCOHOLIC STEATOHEPATITIS | Phase 2 | Status: COMPLETED